Latest / Decera Clinical Education Oncology Podcast
Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy.
Key topics include:
Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs
Identifying patients with…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.